Kinrix™: a new combination DTaP–IPV vaccine for children aged 4–6 years

References

• Edwards KM, Decker MD. Pertussis vaccine. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offitt P (Eds). Saunders, PA, USA 471–528 (2008).
   Google Scholar
• Centers for Disease Control and Prevention. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use – supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm. Rep.41(RR-1), 1–10 (1992).
   PubMedGoogle Scholar
• Plotkin SA, Vidor E. Poliovirus vaccine-inactivated. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offitt P (Eds). Saunders, PA, USA 605–630 (2008).
   Google Scholar
• Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offitt P (Eds). Saunders, PA, USA 631–686 (2008).
   Google Scholar
• Centers for Disease Control and Prevention. Certification of poliomyelitis eradication – the Americas, 1994. MMWR43(39), 720–722 (1994).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Recommended childhood immunization schedule – United States, 1997. MMWR46(2), 35–40 (1997).
   PubMedGoogle Scholar
• Prevots DR, Burr RK, Sutter RW et al. Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recom. Rep.49(RR-5), 1–22 (2000).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0–18 years – United States, 2007. MMWR55(51–52), Q1–Q4 (2006).
   PubMedGoogle Scholar
• Meyerhoff AS, Jacobs RJ. Do too many shots due lead to missed vaccination opportunities? Does it matter? Prev. Med.41(2), 540–544 (2005).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Notice to readers: food and drug administration approval of a fifth acellular pertussis vaccine for use among infants and young children – United States, 2002. MMWR51(26), 574 (2002).
   PubMedGoogle Scholar
• Nilsson L, Faldella G, Jacquet JM et al. A fourth dose of DTPa–IPV vaccine given to 4–6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11–12 months of age. Scand. J. Infect. Dis.37(3), 221–229 (2005).
   PubMed Web of Science ®Google Scholar
• Jacquet JM, Bégué P, Grimprel E et al. Safety and immunogenicity of a combined DTPa–IPV vaccine administered as a booster from 4 years of age: a review. Vaccine24(13), 2440–2448 (2006).
   PubMed Web of Science ®Google Scholar
• Black S, Friedland LR, Schuind A et al. Immunogenicity and safety of a combined DTaP–IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4–6 years. Vaccine24(35–36), 6163–6171 (2006).
   PubMedGoogle Scholar
• Black S, Friedland LR, Ensor K et al. Diphtheria–tetanus–acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4–6 years of age. Pediatr. Infect. Dis. J.27(4), 341–346 (2008).
   PubMedGoogle Scholar
• Marshall H, Nolan T, Roberton D et al. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4–6 years. Vaccine24(35–36), 6120–6128 (2006).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP), US; 2006. MMWR Recomm. Rep.55(RR-15), 574 (2006).
   Google Scholar
• Schmitt HJ, von König CH, Neiss A et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA275(1), 37–41 (1996).
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Schuind A, Knuf M et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J. Pediatr.129(5), 695–701 (1996)
   PubMed Web of Science ®Google Scholar
• Melville-Smith M, Balfour A. Estimation of Corynebacterium diphtheriae antitoxin in human sera: a comparison of an enzyme-linked immunosorbent assay with the toxin neutralisation test. J. Med. Microbiol.25(4), 279–283 (1988).
   PubMed Web of Science ®Google Scholar
• Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J. Biol. Stand.11(2), 137–144 (1983).
   PubMedGoogle Scholar
• Camargo ME, Silveira L, Furuta JA et al. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J. Clin. Microbiol.20(4), 772–774 (1984).
   PubMed Web of Science ®Google Scholar
• Wharton M, Vitek CR. Diphtheria toxoid. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offitt P (Eds). Saunders, PA, USA 211–228 (2008).
   Google Scholar
• World Health Organization. Standard procedure for determining immunity to poliovirus using the microneutralization test. WHO/EPI/Gen93.9. Geneva, Switzerland (1993).
   Google Scholar
• Granström M, Thorén M, Blennow M et al. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur. J. Clin. Microbiol.6(1), 18–21 (1987).
   PubMedGoogle Scholar
• Food and Drug Administration Center for Biologics Evaluation and Research. Open session on adult pertussis. Presented at: Proceedings of a Vaccines and Related Products Advisory Committee. Bethesda, MD, USA, 5 June 1997.
   Google Scholar
• Greco D, Salmaso S, Mastrantonio P et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med.334(6), 341–348 (1996).
   PubMed Web of Science ®Google Scholar
• Braun MM, Mootrey GT, Salvie ME et al. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years’ data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics106(4), 1–7 (2000).
   PubMedGoogle Scholar
• Deloria M, Blackwelder W, Decker M et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics96, 592–594 (1995).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Dunstan M, Starkovich P et al. Prophylaxis with acetaminophen or ibuprofen for prevention of local reactions to the fifth diphtheria–tetanus toxoids–acellular pertussis vaccination: a randomized, controlled trial. Pediatrics117(3), 620–625 (2006).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Use of diphtheria toxoid–tetanus toxoid–acellular pertussis vaccine as a five-dose series. Supplemental recommendations if the Advisory Committee on Immunization Practices (ACIP). MMWR49(RR–13), 1–8 (2000).
   PubMedGoogle Scholar
• Rennels M, Deloria M, Pichichero M et al. Extensive swelling after booster doses of acellular pertussis–tetanus–diphtheria vaccines. Pediatrics105, e12 (2000).
   PubMed Web of Science ®Google Scholar
• Scheifle DW, Halperin SA, Ferguson AC. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin test with vaccine antigens. Vaccine19, 4720–4726 (2001).
   PubMedGoogle Scholar
• Kohl KS, Walop W, Gidudu J et al. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine25(31), 5858–5874 (2007).
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Beutel K, Schuind A et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J. Pediatr.130(4), 616–623 (1997).
   PubMed Web of Science ®Google Scholar
• Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria–tetanus–acellular pertussis vaccines. Semin. Pediatr. Infect. Dis.14(3), 196–198 (2003).
   PubMedGoogle Scholar
• Rowe J, Yerkovich ST, Richmond P et al. Th2-associated local reactions to the acellular diphtheria–tetanus–pertussis vaccine in 4- to 6-year-old children. Infect. Immun,73(12), 8130–8135 (2005).
   PubMed Web of Science ®Google Scholar
• Southern J, Andrews N, Burrage M et al. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine23(29), 3829–3835 (2005).
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Remple VP, Macnabb J et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics112(6 Pt 1), e453 (2003).
   PubMed Web of Science ®Google Scholar
• Rennels M, Black S, Woo E et al. Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose. Pediatr. Infect. Dis. J.25(5), 1–2 (2008).
   Google Scholar
• Langley JM, Predy G, Guasparini R et al. An adolescent-adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4–6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine25(6), 1121–1125 (2007).
   PubMed Web of Science ®Google Scholar
• Scheifele DW, Halperin SA, Ochnio JJ et al. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria–tetanus–acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr. Infect. Dis. J.24(12), 1059–1066 (2005).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. Rep.46(RR-7), 1–25 (1997).
   PubMedGoogle Scholar
• Freed GL, Cowan AE, Clark SJ et al. Use of a new combined vaccine in pediatric practices. Pediatrics118, e251–e257 (2006).
   Google Scholar
• Happe LE, Lunacsek OE, Marshall GS et al. Combination vaccine use and vaccination quality in a managed care population. Am. J. Manag. Care13(9), 506–512 (2007).
   PubMed Web of Science ®Google Scholar
• Marshall GS, Happe LE, Lunacsek OE et al. Use of combination vaccines is associated with improved coverage rates. Pediatr. Infect. Dis. J.26, 496–500 (2007).
   PubMed Web of Science ®Google Scholar
• Kalies H, Grote V, Verstraeten T et al. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr. Infect. Dis. J.25(6), 507–512 (2006).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Supplement to the WHO position paper. Wkly Epidemiol. Rec.81, 137–144 (2006).
   PubMedGoogle Scholar
• Broder KR, Cortese MM, Iskander JK et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.55(RR-3), 1–34 (2004).
   Google Scholar
• Kretsinger K, Broder KR, Cortese MM et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm. Rep.55(RR-17), 1–37 (2006).
   PubMedGoogle Scholar
• Huang LM, Chang LY, Tang H et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria–tetanus–acellular pertussis vaccine in healthy Taiwanese children and adolescents. J. Adolesc. Health37(6), 517 (2005).
   PubMedGoogle Scholar
• Kosuwon P, Warachit B, Hutagalung Y et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria–tetanus–acellular pertussis vaccine (dTpa) administered as a booster to 4–6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine21(27–30), 4194–4200 (2003).
   PubMedGoogle Scholar
• Sänger R, Behre U, Krause KH et al. Booster vaccination and 1-year follow-up of 4–8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur. J. Pediatr.166(12), 1229–1236 (2007).
   PubMedGoogle Scholar
• Robert Koch-Institut: Empfehlung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut zur Pertussis-Schutzimpfung. Epidemiologisches Bulletin3, 21–23 (2006).
   Google Scholar
• Zepp F, Habermehl P, Knuf M et al. Immunogenicity of reduced antigen content tetanus–diphtheria–acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Vaccine25(29), 5248–5252 (2007).
   PubMedGoogle Scholar